Current Share Price Of Jubilant Pharmova
Tracking the current share price of Jubilant Pharmova is essential for investors, analysts, and stakeholders interested in the evolving pharmaceutical and life sciences sector. As a diversified company involved in pharmaceuticals, contract research, radiopharmaceuticals, and proprietary drugs, Jubilant Pharmova’s stock performance is influenced by its financial health, product pipeline, market demand, and overall economic conditions. This topic delves into its latest share price, recent trends, key financial metrics, and factors that may impact its future performance.
Latest Share Price Snapshot
As of the close on July 16, 2025, Jubilant Pharmova’s share price stood at approximately â¹1,194.50 on the NSE, down around 0.68% from the previous session. .
52Week Range and Volatility
- 52Week High: â¹1,309.90 (November 7, 2024)
- 52Week Low: â¹701.80 (July 2024)
The stock has rebounded approximately 65% from its low and is trading 8.8% below its all-time high, demonstrating significant volatility and recovery.
Market Capitalization and Trading Metrics
Jubilant Pharmova carries a market cap around â¹19,000 crore (~â¹19 billion).
According to Moneycontrol, the stock had a volume of approximately 219,949 shares on July 16, with a Volume Weighted Average Price (VWAP) of â¹1,202.52.
Valuation Metrics and Fundamentals
- Price-to-Earnings (P/E): Around 22.722.8Ã based on trailing twelve months
- Price-to-Book (P/B): Approximately 3.05Ã
- Dividend Yield: About 0.42% with the latest dividend of â¹5.0 per share enhancing yields
The trailing P/E of ~22.7Ã is lower than the broader pharmaceutical industry average (~35Ã ), potentially indicating value, though investors should consider the company’s growth prospects.
Recent Financial Performance
Jubilant Pharmova posted a consolidated revenue of â¹1,940.7 crore for the quarter ending March 2025, marking a 6% increase from the preceding quarter.
These results suggest meaningful margin improvement and operational efficiency factors that are often viewed positively by investors and may help sustain the valuation metrics observed.
Key Drivers of Share Price Movement
Radiopharma and CDMO Growth
Jubilant Pharmova’s expansion in radiopharmaceuticals where it ranks third in the US and owns ~46 radio-pharmacies is a key growth driver.
Cost Control and Debt Reduction
Improved working capital from 59.9 days to 30.2 days and ongoing debt reduction have boosted investor confidence.
Macro-Economic and Sector Trends
Pharmaceutical stocks are sensitive to global healthcare trends, patent expirations, and economic cycles. Jubilant Pharmova’s diversified segments generics, sterile injectables, novel drugs mean it may navigate headwinds better than peers, though it remains tied to global macro factors.
Risks and Concerns
- Valuation Risk: While cheaper than industry average, the stock trades at ~3Ã book value. If financial performance slows, this premium may compress.
- Volatility: With strong year-to-date returns (~65%), the stock could see corrections if revenue growth or margins falter.
- Sector-Specific Issues: Changes in US healthcare policy, pricing pressures, or regulatory delays in radiopharma may impact earnings.
Outlook and Analyst Sentiment
Although analyst coverage is mixed, some brokerage reports suggest a Buy rating with 12-month target price ranging from â¹1,300 to â¹1,420, reflecting optimism about growth in radiopharma and contract services.
If the company continues margin improvement and sustains revenue growth, investors may see upside. Conversely, any setbacks in FDA approvals or contract deliveries could weigh heavily on stock performance.
How to Track the Share Price
To track Jubilant Pharmova’s share price and performance effectively:
- Use financial portals like Moneycontrol or Yahoo Finance for live quotes and charts (â¹1,194.50 close)
- Monitor earnings updates and quarterly results for revenue and margins
- Follow company announcements related to dividends, approvals, or strategic partnerships
- Alert platforms usually flag analyst revisions or rating changes
Jubilant Pharmova’s current share price of around â¹1,194 reflects a company that has rebounded strongly from its yearly low, supported by growth in radiopharmaceuticals and improved operational metrics. With respectable valuation multiples and improving financials, the stock may appeal to investors seeking exposure to a diversified pharmaceutical player. However, stakeholders should be mindful of valuation risks, sector volatility, and external pressures. Close monitoring of upcoming financials, FDA updates, and broader market trends will be key to evaluating whether the stock can maintain its momentum or needs reassessment.